MOLECULIN
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
MOLECULIN
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2006-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.moleculin.com
Total Employee:
11+
Status:
Active
Contact:
713) 300-5160
Total Funding:
80.04 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Wolfram C. M. Dempke EU Chief Medical Officer and part-time contractor for its European clinical trials @ Moleculin
EU Chief Medical Officer and part-time contractor for its European clinical trials
2022-04-01
Donald Picker Chief Operating Officer @ Moleculin
Chief Operating Officer
2009-01-01
John Climaco Director @ Moleculin
Director
2017-06-01
ROBERT SHEPARD Chief Medical Officer @ Moleculin
Chief Medical Officer
Robert C. Shepard CMO - Part-time @ Moleculin
CMO - Part-time
2016-07-01
Mike Clinard Director @ Moleculin
Director
2013-01-01
Walter V. Klemp CEO @ Moleculin
CEO
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-10-29 | AnnaMed | AnnaMed acquired by Moleculin | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-04 | Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer |
Official Site Inspections
http://www.moleculin.com Semrush global rank: 4.72 M Semrush visits lastest month: 2 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Moleculin"
About - Moleculin
5300 Memorial Drive, Suite 950 Houston, TX, 77007 info@moleculin.com (713) 300-5160See details»
Moleculin - Crunchbase Company Profile & Funding
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson …See details»
Moleculin Biotech, Inc. | LinkedIn
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors ...See details»
Board of Directors - Moleculin
Since 2006, Mr. Klemp has served as the Chairman, Co-founder and part-time Chief Executive Officer of Moleculin, LLC. From November 2011 to December 2020, Mr. Klemp has served as CEO and then Executive Chairman on the …See details»
Moleculin - Funding, Financials, Valuation & Investors - Crunchbase
Moleculin is registered under the ticker NASDAQ:MBRX . Their stock opened with $6.00 in its Jun 1, 2016 IPO. Moleculin is funded by ROTH Capital Partners. Moleculin has acquired AnnaMed …See details»
Moleculin - Contacts, Employees, Board Members, Advisors
Organization. Moleculin . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Contacts 15. About. …See details»
Moleculin - Overview, News & Similar companies | ZoomInfo.com
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. …See details»
Moleculin Biotech (LON:0K2H) Company Profile & Description
Mar 14, 2025 Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug …See details»
Moleculin Reports Full Year 2024 Financial Results and Provides ...
3 days ago Moleculin Biotech, Inc. – Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025See details»
ex_763052.htm - SEC.gov
Jan 8, 2025 Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 – Received …See details»
Moleculin Receives Positive FDA Guidance for Acceleration of its ...
Feb 13, 2025 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat …See details»
Moleculin Reports Full Year 2024 Financial Results and Provides ...
3 days ago HOUSTON, March 24, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of …See details»
Moleculin Participates in Virtual Investor "What This Means" …
Jan 27, 2025 Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference . Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the …See details»
Moleculin Biotech (MBRX) Company Profile & Description - Stock …
Jun 2, 2016 Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug …See details»
Moleculin to Report Full Year 2024 Financial Results on March 21, …
Mar 19, 2025 Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monda. HOUSTON, March 19, 2025 (GLOBE …See details»
Moleculin Announces Pricing of $3.5 Million Registered Direct …
HOUSTON, Feb. 25, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates …See details»
Moleculin Reports Full Year 2024 Financial Results and
3 days ago Moleculin Biotech, Inc. Unaudited Condensed Consolidated Balance Sheets (in thousands) December 31, 2024 December 31, 2023: Current assets:See details»
Moleculin Reports Full Year 2024 Financial Results and Provides ...
3 days ago Moleculin Biotech, Inc. Unaudited Condensed Consolidated Balance Sheets (in thousands) December 31, 2024 December 31, 2023: Current assets:See details»
All You Need to Know About Moleculin Biotech (MBRX) Rating …
1 day ago Investors might want to bet on Moleculin Biotech, Inc. (MBRX Quick Quote MBRX - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in …See details»
Moleculin Reports Third Quarter 2024 Financial Results and …
Nov 11, 2024 The increase over the prior year period is mainly related to costs incurred for clinical trials (clinical research organization and drug production) and sponsored research …See details»